Statins and safety: can we finally be reassured?

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

8 citing papers in PubMed.

1. Berberine signature and cardiometabolic diseases using randomized controlled trial, cohort study and Mendelian randomization.NPJ cardiovascular health · 2026
   Article
2. Using proteomics to identify the mechanisms underlying the benefits of statins on ischemic heart disease.NPJ cardiovascular health · 2024
   Article
3. Health Outcomes of Population-Based Pharmacy Outreach to Increase Statin Use for Prevention of Cardiovascular Disease in Patients with Diabetes.Journal of managed care & specialty pharmacy · 2016
   Article
4. Clinician's guide to the updated ABCs of cardiovascular disease prevention.Journal of the American Heart Association · 2014
   Review
5. A clinician's guide to the ABCs of cardiovascular disease prevention: the Johns Hopkins Ciccarone Center for the Prevention of Heart Disease and American College of Cardiology Cardiosource Approach to the Million Hearts Initiative.Clinical cardiology · 2013
   Review
6. Fat-free mass and fasting glucose values in patients with and without statin therapy assigned to age groups between <60 and >75 years.Obesity facts · 2013
   Article
7. The importance of matching language to type of evidence: avoiding the pitfalls of reporting outcomes data.Clinical cardiology · 2012
   Article
8. Individualized risk for statin-induced myopathy: current knowledge, emerging challenges and potential solutions.Pharmacogenomics · 2012
   Review

Corrections and comments

• Comment on
  Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomised controlled trial.2011

Authors and funding

2 authors.

Funding

No grant is acknowledged in the PubMed record.

Abstract

PubMed holds no abstract for this paper.

Indexed as